Company intelligence / Profile preview
TME Therapeutics
San Diego, California, United Statestme-tx.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
TME Therapeutics is a biotechnology company focused on developing novel cancer therapies that target the tumor microenvironment (TME). The company's lead research centers on the role of Neuropilin-1 (NRP1) in modulating immune responses and vascularization within tumors. By developing antibodies that specifically inhibit NRP1's interaction with its ligands, TME Therapeutics aims to overcome immune suppression and enhance the efficacy of existing immunotherapies. The company is currently in the pre-clinical stage, advancing its pipeline toward IND-enabling studies for the treatment of various solid tumors.
- Therapeutic areas
- Oncology
- Modalities
- Monoclonal antibodyAntibody
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
Beyond the preview
Go deeper on TME Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TME Therapeutics.